[ET Net News Agency, 30 September 2019] EuroEyes International Eye Clinic Limited
(01846), one of the leading brands in the vision correction industry with German
ophthalmology excellence, said it plans to offer a total of 79.33 million shares under a
global offering (subject to the over-allotment option), which comprises (i) 71.4 million
shares for an international offering, and (ii) 7.93 million shares for the Hong Kong
public offering.
After deducting underwriting fees and estimated expenses, and assuming an offer price of
HK$7.50 per share (being the midpoint of the indicative offer price range between HK$6.20
and HK$8.80 per offer share) and the over-allotment option not being exercised, net
proceeds from the global offering are expected to be HK$526.7 million.
The Hong Kong public offering began today and ends at noon on 8 October. The offer price
and results of allocation will be announced on 14 October. Dealing of EuroEyes' shares on
the stock exchange is expected to commence on 15 October.
BOCI Asia is the sole sponsor and sole global coordinator; while BOCI Asia, China
Securities (International) Corporate Finance Company and Fosun Hani Securities are the
joint book-runners and joint lead managers of the global offering.
EuroEyes ranked first in Germany and second in Denmark in terms of market share in the
advanced lens exchange surgery market and the refractive surgery without PRK/LASEK market.
Among the existing industry participants, the Group was also the first foreign entrant in
the PRC vision correction services market. (KL)